NasdaqGM - Nasdaq Real Time Price ? USD Harrow, Inc. (HROW) Follow Compare 56.42 -1.06 (-1.84%) At close: October 21 at 4:00 PM EDT All News Press Releases SEC Filings All SEC Filings Corporate Changes & Voting Matters Periodic Financial Reports Proxy Statements Tender Offer/Acquisition Reports Offering Registrations 3 US Growth Stocks With High Insider Ownership And 167% Earnings Growth As the U.S. stock market continues to reach new heights, with the Dow Jones Industrial Average marking its 39th record close of the year, investors are increasingly focused on growth opportunities amid strong economic indicators. In this robust environment, stocks with high insider ownership and significant earnings growth can offer compelling prospects for those looking to align their interests with company insiders who have a vested interest in long-term success. Simply Wall St. ? 3 days ago BHRB IBTA HROW -1.84% Melt Pharmaceuticals Announces Dosing of Last Patient in Pivotal Phase 3 Study of Its Lead Product Candidate, MELT-300, for Needle- and Opioid-Free Sedation in Patients Undergoing Cataract Surgery NASHVILLE, Tenn., October 10, 2024--Melt Pharmaceuticals, Inc. ("Melt"), a clinical-stage pharmaceutical company developing novel approaches for procedural sedation, today announced the dosing of the last patient in its pivotal Phase 3 study evaluating the safety and efficacy of its lead product candidate, MELT?300, a non-IV, non-opioid tablet for procedural sedation during cataract surgery. Business Wire ? 11 days ago HROW -1.84% Harrow Relaunches TRIESENCE? NASHVILLE, Tenn., October 03, 2024--Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, announced the relaunch of TRIESENCE? (triamcinolone acetonide injectable suspension) 40 mg/mL, a preservative?free synthetic corticosteroid that is approved by the U.S. Food and Drug Administration (FDA) for visualization during vitrectomy and for the treatment of ocular inflammatory conditions that are unresponsive to topical corticosteroids. Business Wire ? 18 days ago HROW -1.84% Harrow, Inc. (HROW): A Bull Case Theory We came across a bullish thesis on Harrow, Inc. (HROW) on Simon’s Substack by Simon. In this article, we will summarize the bulls’ thesis on HROW. HROW Technologies, Inc.’s share was trading at $44.07 as of Sept 27th. HROW’s trailing P/E was 9.64 according to Yahoo Finance. Harrow (NASDAQ: HROW) is a U.S. pharmaceutical company that develops, […] Insider Monkey ? 19 days ago HROW -1.84% Harrow Announces Nashville Expansion NASHVILLE, Tenn., September 25, 2024--Tennessee Governor Bill Lee, Department of Economic and Community Development Commissioner Stuart C. McWhorter, and Mark L. Baum, Chief Executive Officer of Harrow, Inc. (Nasdaq: HROW), announced today that Harrow is expanding its corporate headquarters in Nashville. Business Wire ? 26 days ago HROW -1.84% Three US Growth Companies With High Insider Ownership In the wake of the Federal Reserve's recent rate cut decision, major U.S. stock indexes have experienced a slight decline as investors digest the implications for future economic growth and inflation control. Amid this backdrop, identifying growth companies with high insider ownership can be particularly appealing to investors seeking stability and alignment of interests between company executives and shareholders. A good stock in today's market often combines robust growth potential with... Simply Wall St. ? last month IBTA ALAB HROW -1.84% Harrow to Present at Three Investor Conferences in September in New York NASHVILLE, Tenn., September 03, 2024--Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, today announced that management will participate in the following three investor conferences in September in New York: Business Wire ? last month HROW -1.84% Harrow Announces Second Quarter 2024 Financial Results NASHVILLE, Tenn., August 07, 2024--Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, announced results for the second quarter and six months ended June 30, 2024. The Company also posted its second quarter Letter to Stockholders and corporate presentation to the "Investors" section of its website, harrow.com. The Company encourages all Harrow stockholders to review these documents, which provide additional details concerning the historical quarterly period and future Business Wire ? 2 months ago HROW -1.84% Harrow To Report Second Quarter 2024 Financial Results After Market Close on August 7, 2024 NASHVILLE, Tenn., July 25, 2024--Harrow (Nasdaq: HROW), a leading U.S. eyecare pharmaceutical company, today announced that it will report its financial results for the second quarter ended June 30, 2024, on Wednesday, August 7, 2024, after the market close. The Company will also post its second quarter Letter to Stockholders to the "Investors" section of its website, harrow.com. Harrow will host a conference call and live webcast at 8:00 a.m. Eastern Time on Thursday, August 8, 2024, to discuss Business Wire ? 2 months ago HROW -1.84% Harrow to Attend 2024 ASRS Annual Meeting NASHVILLE, Tenn., July 12, 2024--Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, today announced that its management team would attend the 2024 American Society of Retina Specialists (ASRS) Annual Meeting, taking place in Stockholm, Sweden, from July 17-20, 2024. The ASRS Annual Meeting brings together top retina specialists, researchers, and industry leaders from around the globe to share the latest advancements and research in retinal health and treatment. Business Wire ? 3 months ago HROW -1.84% Harrow Enters into 340B Prime Vendor Program Contract with Apexus? for IHEEZO? and Other Key Harrow Products NASHVILLE, Tenn., July 09, 2024--Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, today announced that as of July 1, 2024, it has entered into an agreement with Apexus to make IHEEZO? (chloroprocaine hydrochloride ophthalmic gel) 3% and other Harrow products available through its 340B Prime Vendor Program. IHEEZO, indicated for ocular anesthesia, is a low-viscosity topical ocular anesthetic gel with reliable efficacy, a proven safety profile, and simple administrat Business Wire ? 3 months ago HROW -1.84% Harrow Provides TRIESENCE? Relaunch Update NASHVILLE, Tenn., June 20, 2024--Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, is pleased to announce the successful manufacture of the first of three commercial-scale process performance qualification (PPQ) batches of TRIESENCE? (triamcinolone acetonide injectable suspension) 40 mg/mL, a preservative-free synthetic corticosteroid that is FDA?approved for visualization during vitrectomy and for the treatment of ocular inflammatory conditions that are unresponsiv Business Wire ? 3 months ago HROW -1.84% Melt Pharmaceuticals Announces First Patient Dosed in Pivotal Phase 3 Program of Its Lead Product Candidate, MELT-300, for Needle- and Opioid-Free Sedation in Patients Undergoing Cataract Surgery NASHVILLE, Tenn., June 06, 2024--Melt Pharmaceuticals, Inc. ("Melt"), a clinical-stage pharmaceutical company developing novel approaches for procedural sedation, today announced that the first patient has been dosed in its Phase 3 program evaluating the safety and efficacy of its lead product candidate, MELT-300, a non?IV, non-opioid tablet that combines fixed doses of midazolam (3mg) and ketamine (50mg). MELT-300 is administered sublingually using Catalent Inc.’s proprietary fast?dissolving Zy Business Wire ? 4 months ago HROW -1.84% Harrow Announces 52-Week Data from VEVYE? ESSENCE-2 Open-Label Extension Study NASHVILLE, Tenn., June 05, 2024--Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, is pleased to announce results from its ESSENCE?2 open-label extension (OLE) clinical study for VEVYE? (cyclosporine ophthalmic solution) 0.1%, the first and only cyclosporine to treat the signs and symptoms of dry eye disease (DED). ESSENCE-2 OLE was a Phase 3, prospective, multicenter, open-label, clinical study with 202 patients, who had previously completed the ESSENCE?2 study, re Business Wire ? 4 months ago HROW -1.84% Harrow to Present at Two Investor Conferences in May NASHVILLE, Tenn., May 15, 2024--Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, today announced that management will participate in the following two investor conferences in May: Business Wire ? 5 months ago HROW -1.84% Harrow Announces First Quarter 2024 Financial Results NASHVILLE, Tenn., May 13, 2024--Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, announced results for the first quarter ended March 31, 2024. The Company also posted its first quarter Letter to Stockholders and corporate presentation to the "Investors" section of its website, harrow.com. The Company encourages all Harrow stockholders to review these documents, which provide additional details concerning the historical quarterly period and future expectations for t Business Wire ? 5 months ago HROW -1.84% Harrow Names Greg DiPasquale as Senior Vice President, Head of Commercial NASHVILLE, Tenn., May 13, 2024--Harrow (Nasdaq: HROW), a leading U.S. eyecare pharmaceutical company, is pleased to announce the appointment of Greg DiPasquale as Senior Vice President, Head of Commercial, effective immediately. DiPasquale will oversee sales, marketing, and sales operations for Harrow’s rapidly growing portfolio of branded ophthalmic products. This new role reflects Harrow’s commitment to enhancing its leadership structure to support the Company’s continued growth. John Saharek, Business Wire ? 5 months ago HROW -1.84% Harrow Will Release First Quarter 2024 Financial Results After Market Close on May 13, 2024 NASHVILLE, Tenn., April 25, 2024--Harrow (Nasdaq: HROW), a leading U.S. eyecare pharmaceutical company, today announced that it will release its financial results for the first quarter ended March 31, 2024, on Monday, May 13, 2024, after the market close. The Company will also post its first quarter Letter to Stockholders to the "Investors" section of its website, harrow.com. Harrow will host a conference call and live webcast at 8:00 a.m. Eastern Time on Tuesday, May 14, 2024, to discuss the re Business Wire ? 5 months ago HROW -1.84% Melt Pharmaceuticals Closes $24 Million Series B Preferred Stock Financing NASHVILLE, Tenn., April 02, 2024--Melt Pharmaceuticals, Inc. ("Melt"), a clinical?stage pharmaceutical company developing novel approaches for procedural sedation, today announced the completion of its Series B Preferred Stock financing of approximately $24 million from new and existing investors at a pre?money valuation that increased nearly 150% from the pre-money valuation for Melt’s Series A Preferred Stock financing in 2019. The capital raised will primarily support the further development Business Wire ? 6 months ago HROW -1.84% Harrow Health, Inc. (NASDAQ:HROW) Q4 2023 Earnings Call Transcript Harrow Health, Inc. (NASDAQ:HROW) Q4 2023 Earnings Call Transcript March 20, 2024 Harrow Health, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good morning and welcome to Harrow’s Fourth Quarter and Year-End 2023 Earnings Conference Call. My name is […] Insider Monkey ? 6 months ago HROW -1.84% Performance Overview Trailing total returns as of 10/21/2024, which may include dividends or other distributions. Benchmark is S&P 500 Return HROW S&P 500 YTD +403.75% +22.73% 1-Year +291.81% +38.58% 3-Year +461.39% +29.05%
